Biological Effects of Modifications of the Englerin A Glycolate

ACS Med Chem Lett. 2022 Aug 22;13(9):1472-1476. doi: 10.1021/acsmedchemlett.2c00258.

Sarath P D Seenadera ¹, Sarah A Long ¹, Rhone Akee ², Gabriela Bermudez ³, Gregory Parsonage ⁴, Jonathan Strope ⁵, Cody Peer ⁵, W Douglas Figg ⁵, Kathlyn A Parker ³, David J Beech ⁴, John A Beutler ¹

Affiliations

1 Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702 United States.
2 Leidos Biomedical, FNLCR, Frederick, Maryland 21702 United States.
3 Department of Chemistry, Stony Brook University, Stony Brook, New York 11790 United States.
4 School of Medicine, University of Leeds, Leeds, LS2 9JT U.K.
5 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 United States.

PMID: 36105325 DOI: 10.1021/acsmedchemlett.2c00258

Abstract

Modifications at the glycolate moiety of englerin A were made to explore variations at the most sensitive site on the molecule for activity in the NCI 60 screen, wherein englerin A is highly potent and selective for renal Cancer cells. Replacement of the glycolate by Other functionalities as well as esterification of the glycolate hydroxyl yielded compounds which displayed excellent selectivity and potency compared with the natural product. TRPC4/5 ion channel experiments with five compounds showed delayed or reduced agonism with TRPC5, at much higher concentrations than englerin A. With TRPC4, these compounds all had no effect at 10 μM. The same compounds were not detectable in mouse serum after a single oral dose of 12.5 mg/kg. At 100 mg/kg p.o., no toxicity was observed, and blood levels were barely detectable. Intravenous administration led to toxicity but at substantially lower doses than for englerin A.

Name
Email *

	Sorry, but the email address you supplied was invalid.